← All candidates
30 insider filings on record.
30 filings on record.
BVSBioventus Inc.
NasdaqGS · Healthcare · $710.00M
$13.16
+1.39% · Sep 14
30 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 2 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$710.00M
Float
33.3M
49% public
Short % float
Pro
Price / profit
25.6
Price / future profit
11.6
Price / sales
1.2
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
25 more transactions on Pro →Context
Wall St
$14.80 avg target
+12.5% vs today · 5 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 4 quarters beat
Q1 '26$0.15 act+$0.08
Q4 '25$0.24 act+$0.02
Q3 '25$0.15 act+$0.03
Q2 '25$0.21 act+$0.01
Coverage
Zacks.com featured highlights include First Advantage, Bioventus and OomaZacks · 07-07Should Value Investors Buy Bioventus (BVS) Stock?Zacks · 06-25Are Investors Undervaluing Bioventus (BVS) Right Now?Zacks · 06-09Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt FallsMarketBeat · 06-08
The file stays open
30 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice